Get access to our best features
Get access to our best features
Published

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 - Editas Medicine (NASDAQ:EDIT)

Summary by Benzinga
Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)